Fundies. English
Segment disclosures
Company overviewOptiNose, Inc.
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
1 dimension combinations 4 retained observations 4 reported periods
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
Product · Specialty Pharmaceuticals Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ProductMember;us-gaap:StatementBusinessSegmentsAxis=optn:SpecialtyPharmaceuticalsSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2025-01-01 – 2025-03-31 | 18510000 | USD | 20250514 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 78226000 | USD | 20250326 | Open filing evidence |
| 2024-01-01 – 2024-03-31 | 14880000 | USD | 20250514 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 70987000 | USD | 20250326 | Open filing evidence |